- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03163342
Immune Response Following Seasonal Influenza Vaccination
Extent and Durability of Immune Response Following Seasonal Influenza Vaccination in Healthy Volunteers
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Subjects will be screened within 28 days prior to enrollment into the study. After qualifying for the study subjects will visit the clinical unit on Day l and will have pre-dose blood samples taken for humoral (serum) and cellular(peripheral blood mononuclear cells PBMCs) immunity testing and nasopharyngeal swabs for assessment of mucosa! immunity, and will then be given the vaccine.
Over the next 6 months, I 0-mL blood samples will be collected on Days 4, 8, 15, 29, 91 and 181 for HAI testing. Peripheral blood mononuclear cells will be collected on Day 8 to assess cellular responses. A nasopharyngeal swab will also be done on Day 29. Screening assessments will include clinical laboratory tests (hematology, chemistry, urinalysis (UA), drug and alcohol testing), vital signs, 12-lead electrocardiogram and physical examination.
Adverse events (AEs) will be monitored throughout the study.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
Maryland
-
Rockville, Maryland, Forenede Stater, 20850
- Optimal Health Research
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Men and women 18 to 50 years of age, inclusive
- Good general health status, as determined by the Investigator
- Adequate venous access for repeated phlebotomies
- Screening laboratory results within institutional normal range or Grade 1 elevation if the Investigator documents clinical insignificance. Bilirubin may be Grade 2 if associated with no1mal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and the Investigator considers the result not to be clinically significant (e.g. vigorous exercise or Gilbert's syndrome)
- Negative drug and alcohol screen at Screening and pre-dose on Day I
- For women of child bearing potential, negative pregnancy test
- Willingness to practice a highly effective method of contraception that may include, but is not limited to, abstinence, sex only with persons of the same sex,monogamous relationship with a postmenopausal partner, monogamous relationship with vasectomized partner, vasectomy, surgical sterilization (hysterectomy, or bilateral tubal ligation, salpingectomy, or oophorectomy), licensed hormonal methods, intrauterine device (IUD), or consistent use of a barrier method (e.g., condom, diaphragm) with spermicide for 28 days after the Fluzone Intramuscular Quadrivalent vaccine dose.
Exclusion Criteria:
- Pregnant, possibly pregnant, or lactating women
- Body mass index> 35.0 kg/m2
- Positive results for HIV, hepatitis B vims, or hepatitis C virus at Screening
Asthma or other chronic lung disease that is greater than mild in severity. Specifically excluded are participants with any of the following events in the past year:
- Daily symptoms
- Daily use of short acting beta 2 agonists
- Use of inhaled steroids or theophylline
- Use of pulse systemic steroids
- Emergency care or hospitalization related to asthma or other chronic lung disease
- Systemic steroids for asthma exacerbation
- History of diabetes mellitus (gestational diabetes is allowed if treatment was not required postpartum and serum glucose is currently in the normal range)
- History of coronary artery disease, arrhythmia, or congestive heart failure
- Clinically significant ECG abnormality
- Poorly controlled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 95 mmHg) at Screening or pre-dose on Day I
- History of anaphylaxis or angioedema
- Known allergy to any of the ingredients in the vaccine formulation including egg allergy
- History of chronic rhinitis, nasal septal defect,cleft palate, nasal polyps, or other nasal abnormality that might affect vaccine administration
- Previous nasal surgery or nasal cauterization
- Any symptoms of upper respiratory infection or temperature> 38°C within 3 days before Day I
- Significant nasal congestion or rhinorrhea as assessed by the investigator.
- Known or suspected malignancy, excluding non-melanoma skin cancers and other early stage surgically excised malignancies that the Investigator considers to be exceedingly unlikely to recur
- Immunocompromised individuals, including those who have used corticosteroids (including intranasal steroids), alkylating drugs, antimetabolites, radiation, immune-modulating biologics, or other immunomodulating therapies within 90 days before Day 1 or those who plan use during the study period
- Use of statin medication within 30 days before Day I (including atorvastatin, fluvastatin,lovastatin, pravastatin, rosuvastatin, simvastatin, pitavastatin)
- Receipt of intranasal medications (including over-the-counter medications) within 30 days before Day 1
- Receipt of any IP within 30 days before Day 1
- Receipt of any vaccine within 30 days before Day I
- Receipt of intranasal vaccine within 90 days before Day I
- Receipt of any influenza vaccine within 6 months before Day I
- Any change in medication for a chronic medical condition within 30 days before Day I
- Past regular use or current use of intranasal illicit drugs or any regular use of illicit drugs by any other route.
- Use of tobacco products or electronic cigarettes within 30 days before Day l. Any other smoking products including marijuana will be excluded.
- Any medical, psychiatric, or social condition or any occupational or other responsibility that in the judgment of the Investigator would interfere with or serve as a contraindication to protocol adherence, assessment of safety (including immunogenicity), or a subject's ability to give informed consent
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Andet: Open label
Licensed seasonal influenza vaccine, intramuscular
|
20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain
Tidsramme: Day 29 after vaccine
|
To evaluate antibody response against matched influenza strain H1N1 A/California/04/2009 strain as measured by hemagglutination inhibition (HAI) following administration of a seasonal influenza vaccine.
|
Day 29 after vaccine
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Antibody Response to Divergent Influenza Strains
Tidsramme: Day 29 after vaccine
|
l) antibody responses to divergent influenza strains as measured by hemagglutination inhibition (HAI) following administration of a seasonal influenza vaccine
|
Day 29 after vaccine
|
Cellular Immune Response
Tidsramme: Day 8 after vaccine
|
To evaluate cellular immune responses to influenza as measured by PBMC ELISpot following administration of seasonal influenza vaccine
|
Day 8 after vaccine
|
Mucosal Influenza Antibody Response
Tidsramme: Day 29 after vaccine
|
To evaluate mucosal influenza antibody responses as measured by IgA ELISA following administration of seasonal influenza vaccine
|
Day 29 after vaccine
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Stephan Bart, MD, Optimal Health Research
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ALT-FLZ-401
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Influenza
-
Gamaleya Research Institute of Epidemiology and...AfsluttetInfluenza A | Influenza A-virusinfektion | Influenza epidemi | Influenza H5N1Den Russiske Føderation
-
NPO PetrovaxAfsluttetVaccine reaktion | Influenza | Influenza, menneske | Influenza A | Akut luftvejsinfektion | Influenza type B | Influenza | Influenza A H3N2 | Influenza A H1N1 | Influenza, menneske | Influenza epidemiDen Russiske Føderation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectAfsluttetVaccine reaktion | Influenza | Influenza, menneske | Influenza A | Influenza type B | Influenza A H3N2 | Influenza A H1N1Forenede Stater
-
Novartis VaccinesAfsluttetInfluenza | Sæsonbestemt influenza | Menneskelig influenza | Influenza på grund af uspecificeret influenzavirusBelgien
-
SeqirusNovartis VaccinesAfsluttetInfluenza | Influenza, menneske | Influenza A-virus, H5N1-undertype | Influenza, menneske | Influenza, fugleAustralien, Tyskland, Italien
-
Novartis VaccinesNovartis Vaccines and Diagnostics (formerly Chiron Vaccines)AfsluttetInfluenza sygdom; InfluenzaForenede Stater
-
Quidel CorporationAfsluttet
-
National Institute of Allergy and Infectious Diseases...University of Minnesota; International Network for Strategic Initiatives...AfsluttetInfluenza A | Influenza BForenede Stater, Australien, Danmark, Det Forenede Kongerige
-
Ellume Pty LtdAfsluttetInfluenza A | Influenza BAustralien
-
National Institute of Allergy and Infectious Diseases...AfsluttetInfluenza A | Influenza BForenede Stater